How to Beat the cialis once daily Herd Mentality: Highline's Michael Higgins

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 26 February 2015 15:04
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the canadian generic cialis sector, because no stock lives on an island.
Read more...
 

Immuno-Oncology Promises Continued Wealth and where to get viagra cheap Health: LifeTech Capital's Stephen Dunn

Print E-mail
By Staff - The Life Sciences Report   
Thursday, 19 February 2015 15:38

Immuno-oncology disabling cancer's defenses so that a patient's own immune system can seek it out and canadian pharmacy discount code viagra destroy it took center stage in the viagra vs cialis vs levitra which is better drug development world in 2014.

Read more...
 

Bloom Burton's David Martin Zeroes In on Under-the-Radar Biotech

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 12 February 2015 16:26

Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and brand cialis for sale biotech companies based in Canada, where resource stocks have absorbed so much investment capital that many healthcare names have remained hidden and best price zithromax undervalued.

Read more...
 

Capture Growth with Baskets of Biotechs: LifeSci Advisors' Andrew McDonald

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 05 February 2015 19:01
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development.
Read more...
 

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here?

Print E-mail
By Tracy Salcedo-Chourré of The Life Sciences Report   
Thursday, 29 January 2015 18:14
At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and indian cialis generic found every reason to believe its good health would continue into 2015 and beyond.
Read more...
 

What's Next for Biotech in 2015?

Print E-mail
By The Life Science Report   
Thursday, 15 January 2015 08:42
Are life sciences stocks in a bubble? Will this be the year biotech overshadows big pharma?
Read more...
 

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off

Print E-mail
By Sharon di Stefano   
Monday, 12 January 2015 19:19

When peer-reviewed scientific articles publish, especially for investigational medicine, doctors and buy now viagra investors take notice. Few other accolades are held in such high esteem.

Read more...
 

Where Do Cures Reside? Morrie Ruffin and buy nexium online Michael Werner of the Alliance for Regenerative Medicine Think the Answer Is in Regenerative Medicine

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 08 January 2015 18:07

The practice of medicine is being transformed. The journey has been arduous, but revolutionary stem cell, gene and female viagra 2012 immunocellular therapies are rapidly moving toward pivotal milestones—and investors in the space should strap in for a rewarding joy ride.

Read more...
 

Q&A: Actinium Pharmaceuticals Inc. CEO Eyes Orphan Drug Application for Flagship Drug

Print E-mail
By M.E.Garza   
Wednesday, 07 January 2015 00:00

Actinium Pharmaceuticals Inc. a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced last month that the US Food and buy orlistat Drug Administration (FDA) had granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60.

Read more...
 

Pluristem’s Immunotherapy Breakthrough Could Fast-Track GvHD Studies under Japanese Legislation

Print E-mail
By Sharon di Stefano   
Friday, 02 January 2015 16:20

With data in hand that shows evidence its PLX cell therapy produces an immune response, Pluristem Therapeutics (PSTI:NASDAQ) enters the exploding area of immunotherapy, or treating disease via manipulation of the human immune system, and joins the ranks of its larger pharmaceutical counterparts in an industry estimated at $35 billion with fast growth expected in the next seven to eight years.

Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 50

Newsletter

BioMedReports PlasmaTech Announces Initiation of Enrollment of MuGard® Trial for Afinitor®; Ironwood Initiates Phase I Clini... http://t.co/KyllsUrHGp
14hreplyretweetfavorite
BioMedReports Vanda Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus; Aerpio Announces Pub... http://t.co/IxLj84frcl
BioMedReports Bristol-Myers Squibb: ‘This Is the Fastest Approval I’ve Seen’... http://t.co/OFRJjm7sMP